免疫原性
二价(发动机)
血清转化
接种疫苗
病毒学
血凝试验
效价
免疫系统
医学
免疫学
不利影响
相伴的
中和抗体
流感疫苗
抗体
化学
内科学
有机化学
金属
作者
Min Joo Choi,Yeonsil Yu,Jae Won Kim,Ho-Jong Ju,So Youn Shin,Yong Yang,Hee Jin Cheong,Woo Joo Kim,Chulwoo Kim,Hwa Jung Kim,Sunkyung Yoon,Se Jin Park,Won‐Seok Gwak,June-Woo Lee,Byoungguk Kim,Joon Young Song
标识
DOI:10.1016/j.cmi.2024.01.010
摘要
Concomitant COVID-19 and influenza vaccination would be an efficient strategy. Although the co-administration of monovalent COVID-19 and influenza vaccinations showed acceptable immunogenicity, it remains unknown whether the bivalent COVID-19 vaccine could intensify immune interference. We aimed to evaluate the immunogenicity and safety of concomitant BA.5-based bivalent COVID-19 and influenza vaccination.An open-label, nonrandomized clinical trial was conducted for 154 age-matched and sex-matched healthy adults between October 2022 and December 2022. Participants received either a concomitant bivalent COVID-19 mRNA booster and quadrivalent influenza vaccination (group C) or separate vaccinations (group S) at least 4 weeks apart. Solicited and unsolicited adverse events were reported up to 6 months postvaccination. Immunogenicity was evaluated by anti-spike (S) IgG electrochemiluminescence immunoassay, focus reduction neutralization test, and hemagglutination inhibition assay.Group C did not meet the noninferiority criteria for the seroconversion rates of anti-S IgG and neutralizing antibodies against the wild-type SARS-CoV-2 strain compared with group S (44.2% vs. 46.8%, difference of -2.6% [95% CI, -18 to 13.4]; 44.2% vs. 57.1%, difference of -13.0% [95% CI to -28.9 to 2.9]). However, group C showed a stronger postvaccination neutralizing antibody response against Omicron BA.5 (72.7% vs. 64.9%). Postvaccination geometric mean titers for SARS-CoV-2 and influenza strains were similar between groups, except for influenza B/Victoria. Most adverse events were mild and comparable between the study groups.Concomitant administration of bivalent COVID-19 mRNA and quadrivalent influenza vaccines showed tolerable safety profiles and sufficient immunogenicity, particularly attenuating immune imprinting induced by previous ancestral vaccine strains.
科研通智能强力驱动
Strongly Powered by AbleSci AI